Isolated peptides derived from SEQ ID NO: 50 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. The inventive peptides encompasses both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids sequences substituted, deleted, added or inserted, provided such modified versions retain the requisite cytotoxic T cell inducibility of the original sequence. Further provided are nucleic acids encoding any of the aforementioned peptides as well as pharmaceutical agents, substances and/or compositions that include or incorporate any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find particular utility in the treatment of cancers and tumors, including, for example, AML, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, esophagus cancer, Diffused-type gastric cancer, liver cancer, NSCLC, lymphoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal carcinoma, SCLC, soft tissue tumor and testicular tumor.La presente invención se refiere a péptidos aislados derivados de SEQ ID NO: 50 y fragmentos de los mismos que enlazan a un antígeno HLA e inducen linfocitos T citotóxicos (CTL) y de esta manera son adecuados para uso en el contexto de inmunoterapia de cáncer, más particularmente vacunas de cáncer. Los péptidos inventivos abarcan tanto las secuencias de aminoácidos mencionadas arriba y versiones modificadas de los mismos, en los cuales una, dos, o varias secuencias de aminoácidos sustituidas, eliminadas, agregadas o insertadas, proporcionan tales versiones modificadas que mantienen la capacidad de inducción de célula T citotóxica requerida de la secuencia original. Se proporcionan además áci
